Actavis to spend $66B on Botox-maker Allergan

SHARE Actavis to spend $66B on Botox-maker Allergan
SHARE Actavis to spend $66B on Botox-maker Allergan

Actavis is paying $66 billion to buy fellow drugmaker Allergan in a deal that could finally end a months-long takeover battle waged by Valeant Pharmaceuticals for the Botox maker.

Actavis said Monday that it will spend $219 in cash and stock for each share of Allergan.

That tops a bid for Allergan valued at about $53 billion and made last spring by Valeant Pharmaceuticals International Inc. and the hedge fund Pershing Square Capital Management. That offer totaled about $179 in cash and stock.

Allergan resisted the Valeant deal for months, but its board has unanimously approved the Actavis offer.

The Latest
Tops Will Zalatoris in three-hole aggregate playoff at Southern Hills in Tulsa
“Schwisdom” combined for back-to-back homers for the second consecutive day — eighth-inning blasts that gave the Cubs the lead — and newcomer P.J. Higgins hit a three-run triple as the Cubs beat the Diamondbacks 5-4 to salvage the finale of a four-game series.
Reinsdorf — his kingdom for a legit winner! — must be wondering, at least on some level, if he’s ever going to see his basketball team or his baseball team win another championship.
Bail was also denied Sunday for another man who allegedly hid the gun used in the attack, which was equipped with an extended magazine and modified to fire automatically.